Godkendt
Faglig godkendelse: 13.12.2022
Administrativ godkendelse: 10.03.2023
Denne kliniske retningslinje er ikke længere gyldig!
Sproglig revision og opdatering af referencer svarende til hele dokument
Aldersgrænse for delbryststrålebehandling sænkes fra 60 år til 50 år, mens øvrige kriterier fastholdes
På baggrund af DBCG SKAGEN-1 studiet er moderat hypofraktionering med 40 Gy/15F standard ved lokoregional strålebehandling
Anbefaling for indtegning af tumorleje er ændret således at CT snit over/under clips ikke længere inkluderes
På baggrund af konsensusbeslutning anbefales ikke længere markering af cikatrice ved lumpektomi
På baggrund af konsensusbeslutning anbefales bolus alene ved hudinvækst eller inflammatorisk brystkræft
På baggrund af konsensusbeslutning anbefales i videst muligt omfang brug af simultant integreret boost
Efter gennemgang af data fra DBCG HYPO og SKAGEN-1 er tilføjet vejledende percentiler for dosisbegrænsning til ipsilaterale- og kontralaterale lunge, kontralaterale bryst samt hjertet
40% dosiskrav for CTVp-CTVp_tumorbed er fjernet
Tilføjet omtale of protonterapi der som udgangspunkt gives protokolleret
Tilføjet anbefaling om at planlægning af strålebehandling ved primær systemisk behandling forud for operation baseres på oprindelige T- og N-sygdom
Dosisindberetning til DBCG er ændret fra mediandosis til ordineret dosis
Oversigt over historiske stråleterapiteknikker i DBCG
Postoperative radiotherapy is recommended following breast conserving surgery for invasive cancer and/or DCIS and/or pleomorf LCIS, irrespective of patient age (A)
Postoperative, locoregional radiotherapy is recommended for all patients following breast conserving surgery for invasive cancer with T3 disease and/or node positive disease, irrespective of primary tumor size (A)
Postoperative, locoregional radoitherapy is recommended after mastectomy for all patients with one of the following: T3-T4 disease, biopsy-verified node-postive disease, positive surgical margins (A)
Partial breast irradiation is recommended for women ≥50 years, who have had breast conserving surgery for a unifocal, non-lobular breast cancer who fulfill the following criteria: pT1, pN0, ER positive, HER2 normal, grade 1-2, and surgical margins ≥2 mm (A)
Boost after breast conserving surgery is recommended for women ≤49 years at date of diagnosis as well as for women ≥50 years when the surgical margins are positive (A)
In postoperative radiotherapy the recommended radiation dose is 40 Gy/15 Fractions (A)
The recommended dose for sequential boost is the following (A):
40 years or younger: 16 Gy/8 Fractions
41-49 years: 10 Gy/5 fractions
Positive surgical margins: 16 Gy/8 Fractions, irrespective of age
The recommended dose for simultaneous integrated boost is dependent upon the primary radiotherapy and the patient age, cf recommendation no. 7, and is as follows:
40 Gy/15 fractions + 10 Gy/5 fractions: 45,75 Gy /40 Gy /15 fractions
40 Gy/15 fractions + 16 Gy/8 fractions: 52,2 Gy /42,3 Gy /18 fractions
Targets and organs at risk are contoured according to the European Society for Radiotherapy and Oncology (ESTRO) consensus guidelines (D)
For locoregional disease, the extent of the lymph node levels are adjusted to tumor characteristics, N-stage and surgical procedure (+/- axillary lymph node dissection) (D)
It is recommended for postoperative radiotherapy to be classified into seven standard types, A-G, based on localisation and the clinical target volume (D)
It is recommended that postoperative radiotherapy is based on a 3D CT-scanning with a mixamal slice thickness of 3 mm, without iv-contrast, with the patient in the supine position and the ipsilateral arm raised above the head (D)
An external marking of the breast or the chestwall, and of the surgical scar when bolus is used, is recommended (D)
It is recommended ot use a daily bolus for skin invasion or inflammatory breast cancer (D)
Respiratory-gated radiotherapy is recommended for left sided and locoregional treatments (B)
3D conformal planning with a tangential field set-up using photons is recommended as the standard treatment of the breast/chestwall. Periclavicular/axillary fields are to apply an anterior/or posterior field set-up (D)
A simultaneous integrated boost is to be used if at all possible, in boost treatments (D)
It is recommended that radiotherapy plans adhere to the DBCG dose constraints and priorities, as mentioned in Table 4 and 5 (B)
It is recommended that IMRT/VMAT techniques are applied with caution and mean doses to the contralateral organs as lung and breast are to be minimized and should correspond to what can be expected with tangential planning (D)
Proton therapy is considered as an experimental treatment and should be performed within the framework of the DBCG proton trial, SKAGEN II (D)
Set-up verification in the form of kV/kV, kV/MV-imaging, or CBCT is recommended for daily image guidance (D)
Following primary surgery, it is recommended for radiotherapy to start as soon as possible, the maximum time from surgery to start of radiotherapy should not exceed 12 weeks (B)
Following primary surgery, it is recommended to administer chemotherapy first and then start radiotherapy, the time interval from surgery to start of radiotherapy should be as short as possible (A)
The radiotherapy planning for patients who receive systemic treatment prior to surgery should be based on the maximum T- and N-stage, cf recommendations above (D)
It is recommended that patients initiate/continue antihormonal treatment during radiotherapy (if indicated) (D)
Prescribed dose to the CTVp_ partial/_breast/_chestwall including relevant target volumes should be reported to the DBCG database for all patients (C)
Aktuelle retningslinje er gennemgribende opdateret/omskrevet af en arbejdsgruppe bestående af Maja Maraldo og Martin Berg. Medlemmer af radioterapiudvalget, hvor alle radioterapiafdelinger er repræsenteret, har deltaget i høring af retningslinjerne:
Aalborg
Mette Møller, Overlæge, Onkologisk Afdeling, Aalborg Universitetshospital - ingen interessekonflikter.
Ingelise Jensen, Fysiker, Onkologisk Afdeling, Aalborg Universitetshospital - ingen interessekonflikter.
Århus
Birgitte Vrou Offersen, Overlæge Professor, Onkologisk Afdeling, Aarhus Universitetshospital - ingen interessekonflikter.
Esben Yates, Fysiker, Onkologisk Afdeling, Aarhus Universitetshospital - ingen interessekonflikter.
Vejle
Else Maae, Læge PhD, Onkologisk Afdeling, Vejle, Syddansk Universitetshospital - ingen interessekonflikter.
Martin Berg, Fysiker, Onkologisk Afdeling, Vejle, Syddansk Universitetshospital - ingen interessekonflikter.
Odense
Mette Holck Nielsen, Overlæge, Onkologisk Afdeling, Odense Universitetshospital - ingen interessekonflikter.
Ebbe Lorenzen, Fysiker PhD, Onkologisk Afdeling, Odense Universitetshospital. - ingen interessekonflikter.
Næstved
Sami Al Rawi, Overlæge, Onkologisk Afdeling, Sjællands Universitetshospital - ingen interessekonflikter.
Kirsten Legaard Jakobsen, Fysiker, Onkologisk Afdeling, Sjællands Universitetshospital - ingen interessekonflikter.
Herlev
Louise Wichmann Matthiesen, Overlæge PhD, Onkologisk Afdeling, Herlev Universitetshospital - ingen interessekonflikter.
Karen Andersen, Fysiker, Onkologisk Afdeling, Herlev Universitetshospital - ingen interessekonflikter.
Rigshospitalet
Maja Maraldo, Afdelingslæge PhD, Onkologisk Afdeling, Rigshospitalet - ingen interessekonflikter.
Kristian Boye, Fysiker, Onkologisk Klinik, Rigshospitalet - ingen interessekonflikter.
Jf. Habilitetspolitikken henvises til deklaration via Lægemiddelstyrelsens hjemmeside for detaljerede samarbejdsrelationer.
Derudover har andre deltagere i DBCGs RT udvalgs møder haft høringsret og medvirket til ovenstående revision af retningslinjerne, dette gælder særligt for fysikere Harald Spejlborg (Aarhus), Line Bjerregaard Stick (DCPT) og Henrik Nissen (Vejle), afdelingslæger Marie-Louise Milo (Aalborg) og Henrik Villibald Hansen (Rigshospitalet) samt overlæge Saskia Eßer-Naumann (Næstved).
Her har du mulighed for at kontakte Sundhedsvæsenets Kvalitetsinstitut, hvis du har en kommentar til retningslinjen. Ved behov vil instituttet videreformidle til forfatterne af retningslinjen.
Vi gør opmærksom på, at din kommentar ikke må indeholde personfølsomme oplysninger. Vi behandler ikke henvendelser, der vedrører konkrete sygdomsforløb.
(Alle felter skal udfyldes).